Continuous culture of T cells cytotoxic for autologous human leukaemia cells

No abstract is available for this paper.

• Publication year

  1979

• Venue

  Nature

• Publication date

  1979-08-23

• Fields of study

  Medicine, Chemistry

• Identifiers
  DOI 10.1038/280685A0PMID 224318
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Augmentation by interferon of human natural and antibody-dependent cell-mediated cytotoxicity

  1979cited by this paper
• Generation of cytotoxic T lymphocytes to autologous human leukaemia cells by sensitisation to pooled allogeneic normal cells

  1978cited by this paper
• Sensitization of lymphocytes against pooled allogeneic cells. I. Generation of cytotoxicity against autologous human lymphoblastoid cell lines

  1978cited by this paper
• In vitro growth of cytotoxic human lymphocytes. I. Growth of cells sensitized in vitro to alloantigens.

  1978cited by this paper
• Long-term culture of human antigen-specific cytotoxic T-cell lines

  1978cited by this paper
• Autologous leukemia-specific T-cell-mediated lymphocytotoxicity in patients with acute myelogenous leukemia

  1978cited by this paper
• T cell growth factor: parameters of production and a quantitative microassay for activity.

  1978cited by this paper
• Natural cytotoxic reactivity of human lymphocytes against a myeloid cell line: characterization of effector cells.

  1977cited by this paper
• Tumor neutralization, immunotherapy, and chemoimmmunotherapy of a Friend leukemia with cells secondarily sensitized in vitro.

  1977cited by this paper
• Cytotoxic reactivity of human lymphocytes cultured in vitro.

  1977cited by this paper
• Passive transfer of systemic tumor immunity with cells generated in vitro by a secondary immune response to a syngeneic rat gross virus-induced lymphoma.

  1977cited by this paper
• Long term culture of tumour-specific cytotoxic T cells

  1977cited by this paper
• Generation of cytotoxic lymphocytes in vitro against autologous human leukaemia cells

  1976cited by this paper
• Selective in vitro growth of T lymphocytes from normal human bone marrows.

  1976cited by this paper
• Cell-mediated destruction of human leukemic cells by MHC identical lymphocytes: requirement for a proliferative trigger in vitro.

  1976cited by this paper
• Immunotherapy of lethal metastases by lymphocytes sensitized against tumor cells in vitro.

  1975cited by this paper
• Brief communication: In vivo protection against murine plasma cell tumor growth by in vitro activated syngeneic lymphocytes.

  1973cited by this paper
• SHEEP RED CELL BINDING TO HUMAN LYMPHOCYTES TREATED WITH NEURAMINIDASE; ENHANCEMENT OF T CELL BINDING AND IDENTIFICATION OF A SUBPOPULATION OF B CELLS

  1973cited by this paper

• Localization of interleukin-2 in goat ovary

  2012cites this paper
• Adoptive immunotherapy for acute non-lymphocytic leukaemia: a long-term follow up.

  2009cites this paper
• Lysisof Fresh HumanSolidTumorsby AutologousLymphocytesActivated in Vitro with Lectins

  2006cites this paper
• Differences between in Vivoand in Vitro Activation of Cancer Patient Lymphocytes by Recombinant Inter leukin 2 : Possible Role for Lymphokine-activated Killer Cell Infusion in the in F / vo-induccd Activation 1

  2006cites this paper
• Induction of Significant Cytotoxic Activity for Autologous Leukemia Cells: Inverse Correlation between Cytotoxicity and FOXP3 mRNA Expression

  2006cites this paper
• Die Rolle von Interleukin-2 bei der Aktivierung von zytotoxischen T-Lymphozyten

  2005cites this paper
• lymphoma cells Cytotoxicity of interleukin 2-activated lymphocytes for leukemia and

  2005cites this paper
• Recombinant interleukin-2 and lymphokine-activated killer cells in renal cancer patients: I. phenotypic and functional analysis of the peripheral blood mononuclear cells

  2005cites this paper
• Lymphokine-activated suppressor (LAS) cells in patients with gastric carcinoma

  2004cites this paper
• Natural cell-mediated cytotoxicity in vitro and inhibition of tumor growth in vivo by murine lymphoid cells cultured with T cell growth factor (TCGF)

  2004cites this paper
• Human T-cell cultures with selective autotumor reactivity

  2004cites this paper
• Effect of neuraminidase treatment on serum reactivity to autologous leukemic blast cells

  2004cites this paper
• Propagation of cytotoxic effectors from chronic myeloid leukemia patients and cloning of cytotoxic T cells

  2004cites this paper
• In vitro generation of effector cells cytotoxic to autologous targets from chronic myeloid leukemia patients in remission

  2004cites this paper
• 970 THERAPY WITtt LONG-TERM CULTURED CELLS AND INTERLEUKIN

  2003cites this paper
• The effect of autologous tumour vaccine on benzo-a-pyrene induced squamous cell carcinoma of skin in mice

  1997cites this paper
• Theoretical and Literary Evidence for the Existence of the Passive Antitumor Defence System

  1997cites this paper
• Effects of N(G)-Nitro-L-arginine methyl ester, an inhibitor of nitric oxide synthesis, on IL-2-induced LAK cell generation in vivo and in vitro in healthy and tumor-bearing mice.

  1996cites this paper
• Bispecific antibody-mediated cytotoxicity by CD4+ and CD8(+)-activated T cells generated from leukemia patients after allogeneic bone marrow transplantation.

  1995cites this paper
• T cell effector mechanisms in experimental autoimmune uveitis (EAU).

  1995cites this paper
• A method for preparing chelate-cytokine conjugates with retention of protein structure, biological activity, and pharmacokinetic properties.

  1995cites this paper
• Adoptive cellular therapy of urological neoplastic disease.

  1994cites this paper
• The effect of intraportal mannitol on the short-term in vivo distribution of radiolabelled A-LAK cells in rats

  1994cites this paper
• Lowest dose interleukin-2 immunotherapy.

  1993cites this paper
• A bispecific antibody enhances cytokine-induced killer-mediated cytolysis of autologous acute myeloid leukemia cells.

  1993cites this paper
• Analysis of IL-2 functional structure by multiple cysteine substitutions.

  1992cites this paper
• Electron microscopic observation of killer cells induced by mixed culture of lymphocytes with autologous cancer cells and further culture with recombinant interleukin-2.

  1992cites this paper
• Effects of glutathione on the synthesis and turnover of interleukin-2 receptors.

  1992cites this paper
• In vivo modulation of myelin gene expression by human recombinant IL-2.

  1992cites this paper
• Harnessing graft versus leukemia: implications for IL-2 treatment.

  1992cites this paper
• Selective purging by human interleukin‐2 activated lymphocytes of bone marrows contaminated with a lymphoma line or autologous leukaemic cells

  1991cites this paper
• Identification of structural differences between different forms of interleukin-2 (IL-2) using anti-(human recombinant) IL-2 monoclonal antibodies.

  1991cites this paper
• Aberrant regulation of interleukin-2 but not of interferon-gamma gene expression in Down syndrome (trisomy 21).

  1991cites this paper
• Increased lysis of patient CD10-positive leukemic cells by T cells coated with anti-CD3 Fab' antibody cross-linked to anti-CD10 Fab' antibody.

  1991cites this paper
• Cytokines in anticancer therapy.

  1991cites this paper
• Prothymosin alpha enhances interleukin 2 receptor expression in normal human T-lymphocytes.

  1991cites this paper
• Regulation by glutathione of the effect of lymphokines on differentiation of primary activated lymphocytes. Influence of glutathione on cytotoxic activity of CD3-AK-.

  1991cites this paper
• Prothymosin α enhances interleukin 2 receptor expression in normal human T-lymphocytes☆

  1991cites this paper
• Genetic construction and characterization of a fusion protein consisting of a chimeric F(ab') with specificity for carcinomas and human IL-2.

  1991cites this paper
• Cytokines: coordinators of immune and inflammatory responses.

  1990cites this paper
• Mitogenic stimulation of human tumor-infiltrating lymphocytes by secreted factor(s) from human tumor cell lines.

  1990cites this paper
• Differences between in vivo and in vitro activation of cancer patient lymphocytes by recombinant interleukin 2: possible role for lymphokine-activated killer cell infusion in the in vivo-induced activation.

  1989cites this paper
• Visualization of interleukin-2-like molecules in MPP(+)-lesioned rat brain.

  1989cites this paper
• Recombinant interleukin-2 by continuous infusion and adoptive transfer of recombinant interleukin-2-activated cells in patients with advanced cancer.

  1989cites this paper
• Demonstration of the increase in serine esterase-positive T cells in hairy-cell leukemia patients undergoing alpha-interferon therapy.

  1989cites this paper
• Glutathione regulates interleukin-2 activity on cytotoxic T-cells.

  1989cites this paper
• Differential Activation of Lymphokine‐activated Killer Cells with Different Surface Phenotypes by Cultivation with Recombinant Interleukin 2 or T‐cell Growth Factor in Gastric Cancer Patients

  1989cites this paper
• In vivo activation of lymphocytes in melanoma patients receiving escalating doses of recombinant interleukin 2

  1988cites this paper
• Pinocchio cells: morphologically atypical immunologically heterogeneous lymphocytes induced by treatment with interleukin 2.

  1988cites this paper
• Evidence for two discrete phases of IL-2 production in bovine lymphocytes.

  1988cites this paper
• Local administration of autologous lymphokine-activated killer cells and recombinant interleukin 2 to patients with malignant brain tumors.

  1988cites this paper
• Therapy of disseminated tumors by adoptive transfer of specifically immune T cells.

  1988cites this paper
• Influence of natural and recombinant interleukin 2 on endothelial cell arachidonate metabolism. Induction of de novo synthesis of prostaglandin H synthase.

  1988cites this paper
• Endothelial cell function in hemostasis and thrombosis.

  1988cites this paper
• cis-Retinoic acid stimulates the clonal growth of some myeloid leukemia cells in vitro.

  1987cites this paper
• Specific Adoptive Therapy of Disseminated Tumors

  1987cites this paper
• Three-dimensional structure of interleukin-2.

  1987cites this paper
• Bovine interleukin 2: regulatory mechanisms.

  1987cites this paper
• Specific Adoptive Therapy of Disseminated Tumors Requirements for Therapeutic Efficacy and Mechanisms by Which T Cells Mediate Tumor Eradication

  1987cites this paper
• Structure-function analysis of human interleukin-2. Identification of amino acid residues required for biological activity.

  1987cites this paper
• The occurrence of malignant tumors in immunosuppressed states.

  1986cites this paper
• Clonal analysis of cytotoxic T lymphocytes (CTL) against autologous melanoma

  1986cites this paper
• Tumour inhibition by interleukin-2 at the tumour/host interface.

  1986cites this paper
• The effect of aging on the expression of interleukin 2 messenger ribonucleic acid.

  1986cites this paper
• Functional and molecular characterization of a monoclonal antibody against human interleukin 2.

  1986cites this paper
• Cytotoxicity of interleukin 2-activated lymphocytes for leukemia and lymphoma cells.

  1986cites this paper
• Studies of structure-activity relationships of human interleukin-2.

  1986cites this paper
• Simple preparative two-step purification of interleukin-2 from culture medium of lectin stimulated normal human lymphocytes.

  1986cites this paper
• Interleukin-2 and the regulation of natural killer activity in cultured cell populations.

  1985cites this paper
• Harnessing T‐lymphocytes for human cancer immunotherapy

  1985cites this paper
• Generation of T cell growth factor (TCGF)- dependent splenic lymphoid cell line with cell-mediated immunosuppressive reactivity against syngeneic murine tumor.

  1985cites this paper
• Generation of human cytotoxic T lymphocytes against autologous solid tumors by autologous mixed lymphocyte tumor cell culture with T cell growth factor.

  1985cites this paper
• Immunomodulation by environmental contaminants: Asbestos, cadmium, and halogenated biphenyls: A review*

  1985cites this paper
• Lymphokines, monokines, and other cytokines.

  1985cites this paper
• CHAPTER 17 – INDUCTION OF HUMAN SPECIFIC KILLER T CELL AGAINST AUTOLOGOUS CANCER CELLS AND ITS PROPAGATION BY T CELL GROWTH FACTOR

  1985cites this paper
• Treatment of established tumor by adoptive immunotherapy with specifically immune T cells

  1985cites this paper
• Antibodies of predetermined specificity against chemically synthesized peptides of human interleukin 2.

  1984cites this paper
• TRI: Corroding Its Original Intent?

  1984cites this paper
• Lymphokine-activated killer cells: lysis of fresh syngeneic natural killer-resistant murine tumor cells by lymphocytes cultured in interleukin 2.

  1984cites this paper
• Human T-cell growth factor (TCGF).

  1984cites this paper
• Induction of suppressor T cells by interleukin 2.

  1984cites this paper
• Potential for specific cancer therapy with immune T lymphocytes.

  1984cites this paper
• Regulation of the activation of cytotoxic T lymphocytes by prostaglandins and antigens.

  1984cites this paper
• Blocking of the response by human T-lymphocytes to extracts of autologous cancer by monoclonal antibody to Class-I major histocompatibility complex gene products in the leukocyte adherence inhibition assay.

  1984cites this paper
• Bone Marrow Transplantation for Minimal Residual Disease in All in Children: An Overview

  1984cites this paper
• Immunotherapy of patients with glioma: fact, fancy, and future.

  1984cites this paper
• Lymphocyte Transfer for Cancer Therapy

  1984cites this paper
• Requirement for autologous cancer extracts and lipoxygenation of arachidonic acid for human T-cell responses in leukocyte adherence inhibition and transmembrane potential change assays.

  1984cites this paper
• Generation of human cytotoxic T lymphocytes against fresh autologous and allogeneic solid tumors by mixed lymphocyte tumor cell culture with T cell growth factor.

  1984cites this paper
• Therapeutic use of interleukins: Experimental results

  1984cites this paper
• Intralesional injection of interleukin-2-expanded autologous lymphocytes in melanoma and breast cancer patients: a pilot study.

  1984cites this paper
• Allograft Transplant cancer Registry

  1984cites this paper
• Zinc and immunity.

  1984cites this paper
• Rapid expansion of human cytotoxic T cell clones: growth promotion by a heat-labile serum component and by various types of feeder cells.

  1984cites this paper
• Superinduction of human interleukin-2 messenger RNA by inhibitors of translation.

  1984cites this paper
• Control of biologically active interleukin 2 messenger RNA formation in induced human lymphocytes.

  1984cites this paper
• Immunotherapy in the treatment of acute myelogenous leukemia (AML): Rationale, results and future prospects

  1983cites this paper
• Clearance rates and systemic effects of intravenously administered interleukin 2 (IL-2) containing preparations in human subjects.

  1983cites this paper
• Lysis of fresh human tumor cells by autologous peripheral blood lymphocytes and pleural effusion lymphocytes activated by OK432.

  1983cites this paper
• Cytolysis of autologous fresh osteosarcoma cells by human cytotoxic T lymphocytes propagated with T cell growth factor.

  1983cites this paper